Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Non-Cystic Fibrosis Bronchiectasis Market to Showcase Growth at a Minimal CAGR of 2.8% During the Study Period (2019-2032), Assesses DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

03 Apr, 2023, 15:30 GMT

Share this article

Share toX

Share this article

Share toX

The non-cystic fibrosis bronchiectasis (NCFB) market size is anticipated to increase during the forecast period (2023–2032) owing to the increasing awareness and increasing diagnosed prevalent population. Moreover, the expected launch of emerging therapies by leading companies, including AstraZeneca, CSL Behring, Boehringer Ingelheim, and others, will drive the non-cystic fibrosis bronchiectasis market growth

LAS VEGAS, April 3, 2023 /PRNewswire/ -- DelveInsight's Non-Cystic Fibrosis Bronchiectasis Market Insights report includes a comprehensive understanding of current treatment practices, non-cystic fibrosis bronchiectasis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan] and China.

Key Takeaways from the Non-Cystic Fibrosis Bronchiectasis Market Report

  • As per DelveInsight analysis, the non-cystic fibrosis bronchiectasis market size in the 7MM + China was approximately USD 3.4 billion in 2022.
  • According to the assessment done by DelveInsight, the estimated total diagnosed prevalent non-cystic fibrosis bronchiectasis cases in the 7MM + China were approximately 9.3 million in 2022. 
  • Leading non-cystic fibrosis bronchiectasis companies such as Insmed Incorporated, AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, SolAeroMed, Haisco Pharmaceutical, and others are developing novel non-cystic fibrosis bronchiectasis drugs that can be available in the non-cystic fibrosis bronchiectasis market in the coming years.
  • The promising non-cystic fibrosis bronchiectasis therapies in the pipeline include Brensocatib, Colistimethate sodium, CSL787, CHF 6333, BI 1291583, AP-PA02, ARINA-1, S-1226, HSK31858, and others.

Discover which therapies are expected to grab the major non-cystic fibrosis bronchiectasis market share @ Non-Cystic Fibrosis Bronchiectasis Market Report

Non-Cystic Fibrosis Bronchiectasis Overview

Non-cystic fibrosis bronchiectasis (NCFB) is a chronic inflammatory lung disease. It is distinguished by chronic dilatation of the bronchial tree, which results in chronic sputum production and impaired bacterial clearance. The affected lungs develop a vicious cycle of pathogen clearance failure, resulting in frequent infections, chronic inflammation, and ongoing structural damage. Coughing, sputum production, and frequent respiratory infections are the most common non-cystic fibrosis bronchiectasis symptoms.

Patients frequently experience recurring chest infections. Non-cystic fibrosis bronchiectasis symptom severity can vary greatly. Some people have only a few symptoms that appear infrequently, whereas others have a wide range of daily symptoms. If the patient experiences an exacerbation, the symptoms tend to worsen (usually caused by a chest infection). NCFB has a multifactorial etiology, with a high percentage of cases associated with idiopathic, post-infective, COPD, asthma, and other etiologies.

Non-Cystic Fibrosis Bronchiectasis Epidemiology Segmentation

DelveInsight estimates that there were approximately 9.3 million diagnosed prevalent cases of non-cystic fibrosis bronchiectasis in the 7MM + China in 2022.

As per the analysis, China contributed to the largest diagnosed prevalent population of non-cystic fibrosis bronchiectasis, acquiring ~85.64% of the 7MM + China in 2022. These cases are expected to increase further during the study period (2019–2032).

The non-cystic fibrosis bronchiectasis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • NCFB diagnosed prevalent cases
  • NCFB gender-specific cases
  • NCFB severity-specific cases
  • NCFB etiology-associated cases
  • Microbiology of NCFB patients 

Download the report to understand which factors are driving non-cystic fibrosis bronchiectasis epidemiology trends @ NCFB Epidemiological Insights

Non-Cystic Fibrosis Bronchiectasis Treatment Market 

The current non-cystic fibrosis bronchiectasis treatment regimen include antibiotics, corticosteroids, bronchodilators, acid suppression medication, active mucous agents, and bronchial hygiene measures. The presence of neutrophils in the airway lumen suggests a role for anti-inflammatory therapy in this disease. Corticosteroids and macrolides are two classes of anti-inflammatories that are commonly used. However, it is a universal truth that no single non-cystic fibrosis bronchiectasis treatment approach is appropriate for all NCFB patients.

Inhaled antibiotics are generally thought to be more effective and safer than oral and intravenous antibiotics; however, there are differences of opinion on the subject. While interventions reduce the number of exacerbations, sputum production, and bacterial load in the airways, they also cause more localized side effects that can lead to withdrawal. Furthermore, comparative trials on inhaled antibiotics are limited and contentious due to bias in population selection and methodological variability. Moreover, inhaled corticosteroids (ICS) have also been studied in NCFB, with studies comparing the use of high-dose ICS versus medium-dose ICS. Even 7% hypertonic saline nebulized has been found to be safe and effective in addressing sputum retention and thus improving lung function. 

Furthermore, the use of macrolides for non-cystic fibrosis bronchiectasis treatment has become a common approach in recent years due to several characteristics such as their anti-inflammatory effects, ability to decrease mucus production, and well-known effect on Gram-positive cocci and atypical pathogens. Recent evidence shows that long-term treatment with macrolides, particularly azithromycin, significantly reduced the incidence of NCFB exacerbations while also improving quality of life.

To know more about non-cystic fibrosis bronchiectasis treatment guidelines, visit @ Non-Cystic Fibrosis Bronchiectasis Management 

Non-Cystic Fibrosis Bronchiectasis Pipeline Therapies and Key Companies

  • Brensocatib: Insmed Incorporated/AstraZeneca
  • Colistimethate sodium: Zambon
  • CSL787: CSL Behring
  • CHF 6333: Chiesi Farmaceutici
  • BI 1291583: Boehringer Ingelheim
  • AP-PA02: Armata Pharmaceuticals
  • ARINA-1: Renovion
  • S-1226: SolAeroMed
  • HSK31858: Haisco Pharmaceutical

Learn more about the FDA-approved drugs for non-cystic fibrosis bronchiectasis @ Drugs for NCFB Treatment 

Non-Cystic Fibrosis Bronchiectasis Market Dynamics

The dynamics of the non-cystic fibrosis bronchiectasis market are anticipated to be change in the coming years. Disease prevalence is increasing due to improved detection rates with advanced imaging techniques and increased awareness, further boosting the growth of non-cystic fibrosis bronchiectasis.  Moreover, an improved understanding of disease pathophysiology aids in diagnosis and aids in the identification of novel target molecules for treatment development. Furthermore, large, positive, randomized controlled trials are currently in development to establish the standard of care for bronchiectasis patients. In addition, vaccines and monoclonal antibodies are partially useful, but more evidence-based studies are needed to prevent PA chronic colonization in bronchiectasis patients. Thus, the above-mentioned factors will propel the non-cystic fibrosis bronchiectasis market growth.

However, one of the major concerns in understanding the non-cystic fibrosis bronchiectasis market is the lack of evidence to validate many of the interventions used in the day-to-day management of NCFB. There are no global or regional consensus guidelines or any in the United States or Japan. The European Respiratory Society (ERS) recently published guidelines for non-cystic fibrosis bronchiectasis treatment, which clinicians are following. However, there is a discrepancy in data from secondary sources and those in the ERS guidelines. 

Moreover, because of this scarcity, there are gaps in understanding the current non-cystic fibrosis bronchiectasis treatment scenario. Certain studies, however, aid in extrapolating the current situation in which antibiotics remain the mainstay. Furthermore, disease-specific management is difficult because the etiology is often idiopathic. Despite advances in modern medicine, no validated biomarker for NCFB diagnosis, exacerbation assessment, or prognosis has been developed.

Report Metrics

Details

Study Period

2019–2032

Coverage

7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan] and China

Base Year

2019

Non-Cystic Fibrosis Bronchiectasis Market CAGR

2.8 %

Non-Cystic Fibrosis Bronchiectasis Market Size in 2022

USD 3.4 Billion

Key Non-Cystic Fibrosis Bronchiectasis Companies

Insmed Incorporated, AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, SolAeroMed, Haisco Pharmaceutical, and others

Key Pipeline Non-Cystic Fibrosis Bronchiectasis Therapies

Brensocatib, Colistimethate sodium, CSL787, CHF 6333, BI 1291583, AP-PA02, ARINA-1, S-1226, HSK31858, and others

Scope of the Non-Cystic Fibrosis Bronchiectasis Market Report

  • Therapeutic Assessment: Non-Cystic Fibrosis Bronchiectasis current marketed and emerging therapies
  • Non-Cystic Fibrosis Bronchiectasis Market Dynamics: Attribute Analysis of Emerging Non-Cystic Fibrosis Bronchiectasis Drugs 
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL's views, Analyst's views, Non-Cystic Fibrosis Bronchiectasis Market Access and Reimbursement

Discover more about non-cystic fibrosis bronchiectasis drugs in development @ Non-Cystic Fibrosis Bronchiectasis Clinical Trials

Table of Contents

1.

Non-Cystic Fibrosis Bronchiectasis Market Key Insights

2.

Non-Cystic Fibrosis Bronchiectasis Market Report Introduction

3.

Non-Cystic Fibrosis Bronchiectasis Market Overview at a Glance

4.

Non-Cystic Fibrosis Bronchiectasis Market Executive Summary

5.

Disease Background and Overview

6.

Non-Cystic Fibrosis Bronchiectasis Treatment and Management

7.

Non-Cystic Fibrosis Bronchiectasis Epidemiology and Patient Population

8.

Patient Journey

9.

Non-Cystic Fibrosis Bronchiectasis Marketed Drugs

10.

Non-Cystic Fibrosis Bronchiectasis Emerging Drugs

11.

7MM + China Non-Cystic Fibrosis Bronchiectasis Market Analysis

12.

Non-Cystic Fibrosis Bronchiectasis Market Outlook

13.

Potential of Current and Emerging Therapies

14.

KOL Views

15.

Non-Cystic Fibrosis Bronchiectasis Market Drivers

16.

Non-Cystic Fibrosis Bronchiectasis Market Barriers

17.

Unmet Needs

18.

SWOT Analysis

19.

Appendix

20.

DelveInsight Capabilities

21.

Disclaimer

22.

About DelveInsight

Related Reports

Non-Cystic Fibrosis Bronchiectasis Pipeline

Non-Cystic Fibrosis Bronchiectasis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-cystic fibrosis bronchiectasis companies, including Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, among others.

Non-Cystic Fibrosis Bronchiectasis Epidemiology Forecast

Non-Cystic Fibrosis Bronchiectasis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted non-cystic fibrosis bronchiectasis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Bronchiectasis Market

Bronchiectasis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bronchiectasis companies, including RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, among others.

Bronchiectasis Pipeline

Bronchiectasis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key bronchiectasis companies, including RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, among others.

Bronchiectasis Epidemiology

Bronchiectasis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted bronchiectasis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Other Trending Reports

Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market 

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Additionally, get in touch with our business executive to explore @ Healthcare Consulting Services 

Contact Us
Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo:https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Modal title

Also from this source

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

DelveInsight's GPRC5D-directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive...

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

DelveInsight's Sleep Apnea Market Insights report includes a comprehensive understanding of current treatment practices, sleep apnea emerging drugs,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

Biotechnology

Biotechnology

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.